SCHEMBL1697391

SCHEMBL1697391

CC(O)C(C(=O)O)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
ALDH1A1 P00352 1/20 0.50
POLB P06746 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
HPGD P15428 1/20 0.46
MMP9 P14780 2/20 0.45
MMP2 P08253 1/20 0.45
MMP8 P22894 1/20 0.45
MMP13 P45452 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
MMP1 P03956 2/20 0.43
MMP3 P08254 2/20 0.43
MMP7 P09237 1/20 0.42
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13502410 0.90 LMNA (0.48) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL5274618 0.87 MMP9 (0.52) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL5274624 0.87 MMP9 (0.52) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL15329520 0.86 LMNA (0.48) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL15329523 0.86 LMNA (0.48) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL19521043 0.84 ADRA2B (0.51) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL28589379 0.84 LMNA (0.49) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL19521042 0.84 ADRA2B (0.51) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL10315710 0.83 KMT2A (0.47) LMNAALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL15329278 0.83 LMNA (0.51) LMNAALDH1A1POLBHSD17B10L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130123537-A1 PROCESS FOR THE PREPARATION OF LACOSAMIDE AUROBINDO PHARMA LTD. (IN) 2013-05-16 US disclosed
WO-2011144983-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF LACOSAMIDE AUROBINDO PHARMA LIMITED (IN) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123537-A1 PROCESS FOR THE PREPARATION OF LACOSAMIDE MYT1, TET1, LPXN LMNA 878/4885ALDH1A1 2151/4885POLB 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.